Precision medicine: affording the successes of science

[1]  E. Cuppen,et al.  Feasibility of whole‐genome sequencing‐based tumor diagnostics in routine pathology practice , 2022, The Journal of pathology.

[2]  J. Reis-Filho,et al.  Delivering precision oncology to patients with cancer , 2022, Nature Medicine.

[3]  S. Kim,et al.  Firms, states, and global production , 2021 .

[4]  M. Stumpe,et al.  Real-world Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing Data. , 2020, Clinical breast cancer.

[5]  M. Mckee,et al.  Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. , 2020, JAMA.

[6]  Kaanan P. Shah,et al.  Integrated genomic profiling expands clinical options for patients with cancer , 2019, Nature Biotechnology.

[7]  A. Abernethy,et al.  Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer , 2019, Cancer.

[8]  Dawn L Hershman,et al.  Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation , 2019, Journal of the National Cancer Institute.

[9]  T. J. Moore,et al.  Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016 , 2018, JAMA internal medicine.

[10]  M. Berger,et al.  Clinical tumour sequencing for precision oncology: time for a universal strategy , 2018, Nature Reviews Cancer.

[11]  R. Califf,et al.  Real-World Evidence - What Is It and What Can It Tell Us? , 2016, The New England journal of medicine.

[12]  Razelle Kurzrock,et al.  Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. , 2016, JAMA oncology.

[13]  Louis P Garrison,et al.  Private sector risk-sharing agreements in the United States: trends, barriers, and prospects. , 2015, The American journal of managed care.

[14]  H. Kantarjian,et al.  High cancer drug prices in the United States: reasons and proposed solutions. , 2014, Journal of oncology practice.

[15]  H. Kantarjian,et al.  Impact of cancer research bureaucracy on innovation, costs, and patient care. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  L. Zwelling,et al.  Cancer drug prices and the free‐market forces , 2013, Cancer.

[17]  T. Fojo,et al.  Cancer drugs in the United States: Justum Pretium--the just price. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  F. Schmidt.  Meta-Analysis , 2008 .

[19]  J. Verweij,et al.  Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  K. Furuse.  [Phase III study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[21]  R. Campbell.  A Clinician’s Viewpoint , 1994 .

[22]  J. Edmonson,et al.  Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  A. Cruz,et al.  Combination chemotherapy for soft‐tissue sarcomas: A phase III study , 1979, Journal of surgical oncology.